For the Inventor, By the Inventor

Enter assignee name

Innogenetics N.v.

USPTO Granted Patents = 80

CIPO Patents = 7

EPO Patents = 16

Trademarks = 2

Forward Citations = 813

Loading Chart...

Loading Chart...

129 inventors (with patents filed for the assignee):

Geert Maertens (25 out of 42 patents)

Rudi Rossau (23 out of 35 patents)

Hugo Van Heuverswyn (17 out of 27 patents)

4. Lieven Jozef Stuyver (12 out of 30 patents)

5. Geert Jannes (9 out of 11 patents)

6. Eric Saman (9 out of 10 patents)

7. Erik Depla (8 out of 37 patents)

8. Fons Bosman (8 out of 9 patents)

9. Marie-Ange Buyse (6 out of 54 patents)

10. Erwin Sablon (6 out of 12 patents)

11. Eugeen Vanmechelen (6 out of 17 patents)

12. Dirk Pollet (6 out of 6 patents)

13. Hugo Van Heuverswijn (6 out of 6 patents)

14. Robert De Leys (6 out of 12 patents)

15. Bart Vanderborght (6 out of 6 patents)

Core Competencies:

HBV Drug Resistance

HLA Alleles Typing

Amyloid Peptides Antibodies

HCV Envelope Proteins

Fungal Pathogen Detection

Hepatitis C Virus Genotypes

Synthetic Antigens

Immunodominant T-Cell Epitopes

Mycobacterium Resistance Detection

Septic Shock Treatment

Neurological Disease Diagnosis

Isothermal Polymerase Chain Reaction

80 patents: Sort by Forward Citations

1. 8686126 - HBV drug resistance methods (2014-04-01),

2. 8426129 - Method for typing HLA alleles (2013-04-23),

3. 8343493 - Antibodies specific of the β-amyloid peptides and their uses as diagnostic agents or drugs (2013-01-01),

4. 8278432 - HBV drug resistance methods (2012-10-02),

5. 8101351 - Process for typing of HCV isolates (2012-01-24),

6. 7741461 - Nucleic acid probes and methods for detecting clinically important fungal pathogens (2010-06-22),

7. 7422848 - Hepatitis-B viral variants with reduced susceptibility to nucleoside analogs and uses thereof (2008-09-09),

8. 7413741 - HCV E1 comprising specific disulfide bridges (2008-08-19),

9. 7390623 - [object Object] (2008-06-24),

10. 7387879 - Diagnosis of tauopathies (2008-06-17),

11. 7314925 - Constructs and methods for expression of recombinant HCV envelope proteins (2008-01-01),

12. 7313357 - Method for typing and detecting HBV (2007-12-25),

13. 7258977 - Process for typing of HCV isolates (2007-08-21),

14. 7258861 - TNF-derived peptides for use in treating oedema (2007-08-21),

15. 7252936 - Method for the detection of the antibiotic resistance spectrum of Mycobacterium species (2007-08-07),

Innogenetics N.V. is a biotechnology company that specializes in the development and production of diagnostic products. They focus on innovative solutions for the diagnosis and management of infectious diseases, genetic disorders, and neurological conditions. With a strong commitment to scientific excellence and quality, Innogenetics aims to improve patient outcomes and contribute to advancements in healthcare. Visit their website for more information.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

80 Patents

#3 in Ghent

#62 in Belgium

#9,062 in the World

Innogenetics N.v.

Forward Citations = 813

129 inventors:

Geert Maertens (25 out of 42 patents)

Rudi Rossau (23 out of 35 patents)

Hugo Van Heuverswyn (17 out of 27 patents)

4. Lieven Jozef Stuyver (12 out of 30 patents)

5. Geert Jannes (9 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…